SCHEMBL6085763

SCHEMBL6085763

Cc1ccc(C(C)C)c2oc(-c3c[nH]nc3-c3cccc(NC(=O)C(C4CCCCC4)C4CCCCC4)c3)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 7/20 0.37
HPGD P15428 4/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 3/20 0.37
USP2 O75604 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CPT2 P23786 1/20 0.35
CPT1A P50416 1/20 0.35
TSHR P16473 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.34
MAPT P10636 3/20 0.33
THRB P10828 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
AAK1 Q2M2I8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086423 0.89 TSHR (0.46) HPGDALDH1A1KMT2APOLBUSP2
SCHEMBL6086056 0.87 POLB (0.44) HPGDALDH1A1POLBUSP2TSHR
SCHEMBL6084819 0.86 ALDH1A1 (0.44) TP53HPGDMEN1ALDH1A1KMT2A
SCHEMBL6085797 0.86 NPC1 (0.42) TP53HPGDMEN1ALDH1A1KMT2A
SCHEMBL6084903 0.85 MEN1 (0.44) TP53HPGDMEN1ALDH1A1KMT2A
SCHEMBL6083842 0.81 MAPT (0.36) TP53HPGDMEN1ALDH1A1KMT2A
SCHEMBL6083851 0.81 MAPT (0.36) TP53HPGDMEN1ALDH1A1KMT2A
SCHEMBL6202021 0.81 HPGD (0.33) TP53HPGDMEN1ALDH1A1KMT2A
SCHEMBL6085149 0.81 MAOB (0.49) ALDH1A1KMT2APOLBSMN1; SMN2MAPT
SCHEMBL6085011 0.80 TP53 (0.52) TP53HPGDALDH1A1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 TP53 466/4885HPGD 3730/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.